China’s Bribery, Spotty Drug Distribution And IP Gaps Equals … Great Opportunities?
This article was originally published in PharmAsia News
It is no secret that China is seen as a key growth market for the pharmaceutical industry. But as appealing as the country's skyrocketing market is to companies, many barriers to expansion, including IP concerns and a slowly improving drug distribution system - remain
You may also be interested in...
SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years
BEIJING - As part of sweeping health system reforms that China is charting out for the next decade, the government is now mulling over how to change its price caps on medicines and how to formulate or approve pricing for virtually every drug on the market
BEIJING - China's Supreme People's Court has issued a legal document that will make it easier and more likely for doctors accepting bribes to be prosecuted under the country's criminal law